Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
CDMO to develop, manufacture monoconal antibody for treatment, prevention of infection with COVID-19 virus for Department of Defense
March 24, 2020
By: Tim Wright
Editor-in-Chief, Contract Pharma
The Department of Defense (DOD) awarded a contract valued at $14 million to Ology Bioservices, a biologics contract development and manufacturing organization (CDMO), to develop and manufacture a monoclonal antibody for treatment and prevention of infection with the COVID-19 virus.
This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency.
Under this program, Ology Bioservices will work with Vanderbilt University Medical Center (VUMC) in Nashville, TN to develop and manufacture the monoclonal antibody. The aim of the program is to rapidly and efficiently deliver the antibody to the Department of Defense.
“We are tremendously honored to be working with the Department of Defense and Vanderbilt University Medical Center to rapidly respond to this crisis,” said Peter Khoury, president and chief executive officer, Ology Bioservices. “The Advanced Development and Manufacturing Facility operated by Ology Bioservices stands ready to meet the needs of the U.S. warfighter and the nation at large.”
Douglas Bryce, Joint Program Executive Officer for Chemical, Biological, Radiological and Nuclear (CBRN) Defense, said, “The global health crisis we’re seeing unfold right now with the coronavirus disease 2019 is exactly the kind of scenario the medical countermeasures Advanced Development and Manufacturing Facility was built for. It gives DOD and interagency partners like Health and Human Services, along with our partners in industry and academia, the ability to respond quickly and develop the treatments our warfighters need to fight COVID-19 so they can continue protecting the nation.”
Matthew Hepburn, M.D., Joint Project Lead CBRN Defense Enabling Biotechnologies, added, “This contract represents the realization of the prior investment in the DOD Advanced Development and Manufacturing Facility, in order to respond to biological threats and pandemics. The Ology Bioservices team will now endeavor to make a product to keep DOD personnel safe.”
Under the proposed terms of a pending agreement with VUMC, researchers in the Vanderbilt Vaccine Center (VVC) will be tasked in this program with rapid antibody discovery efforts as a performance site for the Pandemic Prevention Platform (P3) network of the U.S. Defense Advanced Research Projects Agency (DARPA).
“Our team has been pushing 24/7 to isolate human monoclonal antibodies for SARS-CoV-2, and we are gratified to have the partnership of Ology Bioservices and the support of the U.S. DOD to prepare clinical grade antibody materials for rapid testing in clinical trials,” said James Crowe, M.D., director of the Vanderbilt Vaccine Center.
“This collaborative effort with the U.S. DOD Enabling Biotechnologies Office is a natural extension of our current effort to rapidly discover and deploy protective monoclonal antibodies for SARS-CoV-2 through the DARPA Pandemic Prevention Program (P3),” added VVC Associate Director Robert H. Carnahan, Ph.D. “Partnering with Ology Bioservices will allow these antibodies to quickly move towards human clinical trials in the coming months.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !